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A bst ract
Background and purpose: At present, more than 20 differ-
ent forms of limb-girdle muscular dystrophies (LGMDs)
are known (at least 7 autosomal dominant and 14 autosomal
recessive). Although these different forms show some typical
phenotypic characteristics, the existing clinical overlap makes
their differential diagnosis difficult. Limb-girdle muscular
dystrophy type 2 (LGMD2A) is the most prevalent LGMD
in many European as well as Brazilian communities and is
caus ed by mutations in the gene CAPN3. Laboratory testing,
such as calpain immunohistochemistry and Western-blot
analysis, is not totally reliable, since up to 20% of molecularly
confirmed LGMD2A show normal content of calpain 3 and
a third of LGMD2A biopsies have normal calpain 3 proteo -
lytic activity in the muscle. Thus, genetic testing is consid-
ered as the only reliable diagnostic criterion in LGMD2A.
Material and methods: In an attempt to find a correlation
between genotype and muscle pathology in limb-girdle mus-
cular dystrophy 2A we performed histopathological investi-
gation of a group of 31 patients subdivided according to the
type of pathologic CAPN3 gene mutation.
Results: In all biopsies typical features of muscular dystro-
phy such as fiber necrosis and regeneration, variation in fiber
size and fibrosis were noted. Lobulated fibers were often
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St r eszc zenie
Wstêp i cel pracy: Dotychczas opisano ponad 20 ró¿nych form
dystrofii obrêczowo-koñczynowej (limb girdle muscular dystro-
phy – LGMD) (co najmniej 7 rodzajów o dziedziczeniu auto-
somalnym dominuj¹cym oraz 14 o dziedziczeniu autosomal-
nym recesywnym). Pomimo ¿e czêœæ z tych chorób mo¿na
ró¿nicowaæ na podstawie obrazu klinicznego, diagnostykê
utrudnia czêsto podobieñstwo objawów. Dystrofia obrêczowo-
-koñczynowa typu 2A (limb-girdle muscular dystrophy type 2 –
LGMD2A), najczêstsza dystrofia miêœniowa w wielu spo³ecz-
noœciach (np. w Europie i Brazylii), spowodowana jest przez
mutacje w genie kalpainy 3 (CAPN3). Badanie immunohisto-
chemiczne kalpainy czy te¿ metod¹ Western blot nie s¹ wystar-
czaj¹ce do ustalenia w³aœciwego rozpoznania (w odpowiednio
1/3 i 20% potwierdzonych genetycznie LGMD2A badania te
wypadaj¹ prawid³owo). Podstawê rozpoznania tej miopatii sta-
nowi badanie genetyczne. 
Materia³ i metody: W pracy przedstawiono wyniki badania
zale¿noœci miêdzy genotypem a analiz¹ histopatologiczn¹ biop-
sji miêœnia u 31 chorych na LGMD2A. Chorzy podzieleni
zostali na grupy wed³ug wyników badania genetycznego genu
CAPN3 odpowiedzialnego za tê chorobê.
Wyniki:We wszystkich badanych biopsjach stwierdzano typowe
zmiany dystroficzne, takie jak obecnoœæ w³ókien martwiczych
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Introduction
Limb girdle muscular dystrophies (LGMDs) rep-
resent a heterogeneous group of disorders with variable
clinical and genetic features. Limb girdle muscular 
dystrophies are characterized clinically by progressive
muscle weakness and atrophy mainly of the pelvic and
shoulder girdle muscles but without affecting facial mus-
cles. The clinical course may be variable, ranging from
severe forms with early onset and rapid progression to
milder forms with later onset and minor physical dis-
ability [1,2]. However, in all cases serum creatine kinase
is elevated and a dystrophic pattern with necrosis and
regeneration on the muscle biopsy is observed. At pre-
sent, more than 20 different forms of LGMDs are
known (at least 7 autosomal dominant and 14 autoso-
mal recessive) [3]. Although these different forms show
some typical phenotypic characteristics, the existing cli -
nical overlap makes their differential diagnosis difficult
[3,4]. Labo ratory testing, such as calpain immunohis-
toche mistry [5] and Western-blot analysis, is not total-
ly reliable, since up to 20% of molecularly confirmed
limb-girdle muscular dystrophy type 2 (LGMD2A)
show normal content of calpain 3 [6-9] and a third of
LGMD2A biopsies have normal calpain 3 proteoly-
tic activity in the muscle [10]. Thus, genetic testing is
considered as the only reliable diagnostic criterion in
LGMDs [11-14].
A classic LGMD2 phenotype was described by
Fardeau in 1996 [15] in a small community living in
the Reunion Island. Since then, LGMD2A has been
identified in many countries [3,13,21-24]. Subsequently,
wide intra- and interfamilial variability has been report-
ed [8,14,25,26]. Limb-girdle muscular dystrophy type
2 is the most prevalent LGMD in many European as
well as Brazilian communities [20,21,23,27,28]. 
Mutations in the calpain (CAPN3) gene have been
proven to be responsible for LGMD2A (MIM# 53600)
[29,30]. Until now, more than 160 pathogenic muta-
tions have been identified. However, lack of defined
mutational hotspots makes molecular analysis laborious
and expensive [14].
Calpain 3 is a skeletal, muscle specific, Ca2+-activat-
ed neutral protease [30]. The physiological role of cal-
 pain 3 in muscle cell is still uncertain [14]. Spencer 
et al.,[25] and Keira et al. [31] described calpain 3 bind-
ing to the N2 and M-line regions of titin. This binding
is thought to stabilize calpain 3, preventing its autolysis.
It has been shown that calpain 3 is involved in the disas-
sembly of myofibrils during early stages of turnover [32]
and plays a role in the postfusion defect in muscle matu-
ration and differentiation [33,34]. As for the LGMD2
patholo gical mechanism, it is now well accepted that loss
of fun ction mutation leads to abnormal sarcomere for-
mation and impairment of muscle protein capacity [35].
Numerous myopathological changes typical for mus-
cular dystrophy have been described in LGMD2A
patients [19,36,37]. Basic histological and histochemi -
cal features of the muscle biopsy are relatively non-spe-
cific. However, the presence of abnormal lobulation of
type 1 fibers in the end stage of the disease was found by
Fardeau et al. [15] already in the Reunion Island pa -
tients. Subsequently, the high proportion of lobulated
fibers in muscle biopsy was considered as a hallmark of
pathological lesions of calpainopathy [38,39].
Fanin et al. [40] in their description of 24 LGMD2A
patients found significantly lower levels of dystrophic
features (i.e. degenerating and regenerating fibers) and
higher levels of chronic changes (i.e. lobulated fibers)
as compared with other types of LGMD2A. Lobulat-
ed fibers, so called because of their peculiar pattern of
oxidative enzyme reaction on histochemical preparations,
represent a non-specific muscle pathology, observed in
a variety of neuromuscular disorders [41]. They have
been described in both genetic (facioscapulohumeral
muscular dystrophy, Duchenne carrier, alpha-sarcogly-
canopathy, myoto nic dystrophy type 2) [10,42,43] and
acquired myo pathies (dermatomyositis, polymyositis and
encountered in the muscle biopsies of LGMD2A patients.
Such fibers were more frequent in patients with 550delA
mutation.
Conclusions: These findings may be helpful in establishing
diagnostic strategies in LGMD.
Key words: limb girdle muscular dystrophy, CAPN3, calpain,
muscle biopsy.
i regeneruj¹cych, zró¿nicowan¹ wielkoœæ w³ókien oraz w³óknie-
nie. W³ókna o nierównomiernym rozk³adzie barwieñ na
enzymy oddechowe (lobulated fibers) by³y czêsto obserwowane
w biopsjach chorych z LGMD2A. Tego typu w³ókna szczegól-
nie czêsto wystêpowa³y u chorych z mutacj¹ 550delA.
Wnioski: Wyniki pracy wnosz¹ nowe informacje u³atwiaj¹ce
diagnostykê LGMD.
S³owa kluczowe: dystrofia obrêczowo-koñczynowa, CAPN3,
kalpaina, biopsja miêœni.
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adult nemaline myopathy) [44-47]. Interestingly, they
were also reported in neurogenic muscle disease [48]
and dystonia [49].
The exact pathomechanism leading to the forma -
tion of lobulated fibers remains to be elucidated. In
LGMD2A, the loss of calpain activity on myofibrils
leads to incomplete muscle maturation and this hypo-
thesis is currently taken into consideration [25,38]. 
The question of selective involvement of type 1 muscle
fibers still remains unanswered.
To provide detailed histopathological characteristics
in a large group of patients with calpainopathy, we eval-




Out of our group of 68 patients with genetically
proven LGMD2A, we have studied 31 cases (15 females
and 16 males) who had a muscle biopsy taken for diag-
nostic purposes during the period from 1992 to 2002.
There was no family history of myopathy in all diagnosed
patients.
Molecular genetic analysis: DNA testing for calpain 3
gene mutations
Mutation analysis in the CAPN3 gene was done 
by single strand conformation polymorphism (SSCP) and
heteroduplex (HE) analysis according to previously
described procedures [30,50]. Polymerase chain reaction
products revealing an abnormal SSCP/HE migration
pattern were directly sequenced on an ABI PRISM 377
automated fluorescent DNA sequencer (Applied Biosys-
tems) in the DNA Sequencing and Oligonucleotide 
Synthesis Laboratory, IBB PAN, Warsaw, Poland.
Muscle biopsy specimens
Amuscle biopsy was performed on the vastus femoris
muscle in all patients according to a previously described
method [51]. Detailed data on light microscopic evalu-
ations were performed on transverse sections conven-
tionally stained with hematoxylin-eosin (H&E), Gomori
trichrome, NADH dehydrogenase, succinic dehydro-
genase (SDH), lactic dehydrogenase (LDH) and ATPase
after preincubation at pH 9.4 and 4.35. 
For the purpose of this study, all samples were reeval-
uated by two authors in non-blinded analysis (A.N.-P.
and A.K.). Pathological changes such as necrosis 
and regeneration, fibrosis, hyaline fibers, ring fibers 
and muscle fiber type composition were assessed semi-
quantitatively in every case. Changes were graded on
a 4-point scale: none (–), mild (+), moderate (++), or
advanced (+++). Necrosis and other structural
changes were assessed in selected areas in H&E stain-
ing, whereas fiber type composition and lobulated fibers
were assessed in serial sections in the same area in SDH.
Lobulated fibers were defined as fibers with a cha -
racteristic peculiar pattern of oxidative enzyme reaction
on histochemical preparations.
As for fiber type composition [52], the following
approximate proportions were accepted: type 1 – 30-40%
and type 2 – 60-70%.
Results
Clinical and genetic data of 31 patients are summa-
rized in Tables 1, 2 and 3.
Patient Sex Age at Age at 
number onset biopsy
1 F 12 12
2 M 14 23
3 F 12 14
4 F 13 15
5 M 9 17
6 M 6 13
7 F 18 25
8 M 12 14
9 F 11 13
10 F 12 16
11 F 10 27
12 F 5 18
13 M 14 15
14 M 14 14
15 F 2 23
16 M 11 12
Table 1. Clinical and genetic description of subjects. Group 1: Patients with
homozygous del550A mutation
F – female, M – male
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All patients were sporadic and had limb-girdle clin-
ical phenotype. Patients were divided according to the
mutation. In 16 patients, the homozygous occurrence of
550delA mutation was detected (group 1). In 5 patients
different homozygous mutations other than 550delA
were demonstrated (group 2) and the remaining 10 pa -
tients were compound heterozygotes for previously des -
cribed mutations in the CAPN3 gene (group 3).
Group 1 (Table 1) consisted of 16 patients (9 males
and 7 females). The mean age at onset of muscle symp-
toms was 10.9 years (range: 2-18 years). Group 2 
(Table 2) consisted of 5 patients (1 female and 4 males).
The mean age at onset was 12.5 years (range: 6-15 years).
Group 3 (Table 3) consisted of 10 patients (4 females and
6 males). The mean age of onset was 15 years (range:
2-20 years).
All examined patients had myopathic changes in
muscle biopsy. A constant feature, observed in all exam-
ined biopsies, was increased variability in fiber size and
fibrosis. The other common feature typical for muscu-
lar dystrophy was fiber necrosis (27/31) and regenera-
tion (30/31). Only one biopsy showed neither necrosis
nor regeneration. The occurrence of hyaline fibers was
frequent (21/31), whereas ring fibers were rarely en -
countered (5/31).
Intensity of all analyzed histopathological changes
varied from ‘none’ to ‘advanced’ and seemed not to be
correlated with either age of the patient or the duration
of the disease. It was noted, however, that in group 1
fibrosis tended to increase as the disease progressed. No
such relationship was observed in other groups. Occur-
rence of lobulated fibers was found in more than half 
of the biopsies (17/31). Such fibers behaved mostly as
type 1 fibers.
No significant differences were observed between
groups with different mutations except for the high per-
centage of lobulated fibers in group 1 (patients homozy-
gous for del550A mutation). In this group, lobulated
fibers were noted in almost 2/3 of cases (10/16). No cor-
relation between the duration of the disease and the
Patient Sex Age at Age at Mutation
number onset biopsy
1 M 2 11 hz 418dupC,fs
2 M 8 14 hz 418dupC,fs
3 M 20 30 hz 598-612del15ntd Phe200_Leu204del
4 F 11 12 hz 598-612del15ntd Phe200_Leu204del
5 M 13 18 hz 598-612del15ntd Phe200_Leu204del
Table 2. Clinical and genetic description of subjects. Group 2: Patients with different homozygous mutations other than del550A
M – male, F – female
Patient Sex Age at Age at Mutation
number onset biopsy
1 F 10 12 htz del550A, 2242C>T Arg 748stop
2 M 7 9 02 htz del550A, htz del598-612, The 200-204 FWSAL
3 F 10 15 htz del550A, htz509A>G Tyr170Cys(new)
4 M 13 15 htz del550A, 2242C>T Arg 748stop
5 F 12 15 htz del550A, htz649G>A, Glu 217Lys
6 M 12 15 htz del550A, 1722delC fs(new)
7 F 15 19 htz del550A, htz del598-612, The 200-204
8 M 6 6 htz del550A, htz1356insT,fs
9 M 14 20 htz 1063C>T Arg355Trp, htz 1194-9A>G fs
10 M 10 10 htz del550A, 418dupC fs
Table 3. Clinical and genetic description of subjects. Group 3: Patients with different heterozygous mutations
F – female, M – male
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num ber of lobulated fibers was noted. For instance, 
in the group of 4 patients with longstanding disease 
(< 10 years) only 1 had lobulated fibers. In group 2,
only 1 of 5 biopsies showed the occurrence of lobulated
fibers. In group 3, lobulated fibers were noted in half 
of the patients. Type 1 fiber predominance was observed
in one third of biopsies (10/31) while type 2 fiber pre-
dominance was very seldom seen (3/31).
Lobulated muscle fibers were characterized by an
irregular pattern of oxidative enzyme reaction in light
microscopy (Fig. 1). Most of them were atrophied and
behaved as type 1 fibers.
Discussion
In our analysis, we confirmed the presence of typi-
cal dystrophic pathological changes in the muscle biop-
sies with genetically proven LGMD2A. As in other
muscular dystrophies, LGMD2A muscles show active
necrotic and regenerating processes resulting, as the dis-
ease progresses, in increased fiber size variation and
fibrosis. The intensity of the dystrophic process did not
vary across the three groups with different mutations
and seemed not to correlate with the age of the onset and
disease duration, except for more pronounced fibrosis
in patients with longstanding disease.
Histopathological investigations of muscle biopsies
in LGMD2A patients are scarce [19,26,36,53]. Three
of these studies [19,36,53] dealt with systematic reviews,
whereas Vainzof et al. [24] described preclinical histo -
pathological changes in muscle biopsies from members
of a large consanguineous family. Chae et al. [36] in all
patients with CAPN3 mutations found the typical fea-
ture of muscular dystrophy with less active necrosis and
prominent fibrosis in the advanced stages of the disease.
Similar observations were presented by Hermanova 
et al. [19]. In a group of 12 LGMD2A patients, a less
active necrotic process was observed in patients with
longstanding disease. The extent of fibrosis, however,
correlated with the disease duration.
According to Fanin et al. [53], in their series of 24
LGMD2A patients the level of dystrophic features (i.e.
degenerating and regenerating fibers) was significantly
lower than in other types of LGMD2. The authors also
found a direct correlation between the extent of muscle
fiber degeneration and regeneration and disease pro-
gression. In their group, the histopathology severity
score seemed not to be correlated with disease duration.
Yet, a correlation between the extent of fibrosis and 
disease duration was found in our patients only in sub-
 group 1 of LGMD2A homozygous for del550A muta-
tion. No such correlations were found in the other sub-
groups. 
There are only a few studies that have analyzed the
presence of lobulated fibers in genetically confirmed
Fig. 1. Multiple lobulated fibers with irregular aggregations of oxidative acti-
vity within the cytoplasm. Note also the presence of the ring fiber (arrow) as
well as the presence of normal type I (arrowheads) and type 2 (asterisk) fibers.
Succinic dehydrogenase × 20
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LGMD2A patients. None of them, however, correlated
the histopathological findings with the type of CAPN3
mutation. Chae et al. [36] found a high proportion (67%)
of lobulated fibers in his series of 21 patients as well as
a positive correlation between the number of lobulated
fibers and the stage of the disease. 
Hermanova et al. [19], in their material of 14 mus-
cle biopsies, revealed lobulated fibers in half of the spec-
imens. They observed that most lobulated fibers were
found in muscle biopsies performed after a longstand-
ing disease course and were not found in the early stages
of the disease. Fanin’s findings [53] also confirmed the
occurrence of lobulated fibers in a high percentage of
cases (13 from a group of 24 patients). Similarly, they
observed a correlation between the number of lobulated
fibers and disease duration.
In our patients, lobulated fibers were found in more
than half of the biopsies in the group of 31 LGMD2A
cases. No obvious association between lobulated fibers
and disease duration was observed in the analyzed group.
We performed the first, to our knowledge, histo -
pathological investigation of a group of LGMD2A
patients, subdivided according to the type of pathogenic
mutation. 
No Fiber type Necrosis Regeneration Increase Hyaline Fibrosis Ring Lobulated
pre- in fiber fibers fibers fibers
dominance variability
1 Type 1 + + + +++ ++ – ++
2 Type 1 +++ +++ +++ ++ + – –
3 Type 1 + +++ ++ + + – –
4 Type 1 ++ +++ ++ ++ + – +
5 Type 1 +++ +++ ++ ++ ++ + –
6 Type 1 + ++ ++ – + – +++
7 - + ++ ++ ++ +++ ++ ++
8 - +++ +++ +++ + +++ – +
9 - + +++ + + ++ – –
10 - + + ++ – ++ – +++
11 - – ++ + +++ +++ – –
12 Type 2 + + + +++ + + +++
13 Type 2 + ++ + + + – –
14 - + ++ + ++ + – ++
15 - – ++ ++ + + – +
16 - ++ ++ + – + – +
Table 4. Occurrence of muscle histopathological changes in patients with homozygous del550A mutation (Group 1)
No Fiber type Necrosis Regeneration Increase Hyaline Fibrosis Ring Lobulated
pre- in fiber fibers fibers fibers
dominance variability
1 – – – ++ + + – –
2 – ++ ++ ++ + ++ + ++
3 Type 1 – – + – + – –
4 – +++ +++ ++ ++ ++ – –
5 – + ++ + ++ +++ – – 
Table 5. Occurrence of muscle histopathological changes in patients with different homozygous mutations other than del550A (Group 2)
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The only relation we found was a higher occurrence
of lobulated fibers in patients homozygous for del550A
mutation.
Genotype-phenotype correlations in LGMD2A have
been described so far in only two papers [19,53]. Fanin
et al. [53], however, concentrated on the relationship
between genotype and protein content in muscle. Saenz
et al. [50] analyzed the clinical status of patients with dif-
ferent mutations and suggested that patients with homo -
zygous mutations tend to have a more severe phenotype
and faster clinical course. Neither of these studies took
muscle morphology into consideration.
Limb-girdle muscular dystrophy type 2 remains one
of the most difficult of all recessive LGMDs to diag-
nose. The variability of clinical phenotype, incomplete
sensitivity and specificity of calpain 3 protein biochemi-
cal analysis [30], and the effort required to identify point
mutations in a relatively large gene make the diagnostic
process a complicated, laborious and expensive task. Yet,
an unequivocal diagnosis is necessary, both when offer-
ing genetic counseling and when selecting patients for
future clinical trials with drug or gene therapy.
Conclusions
In our opinion, distinguishing the patterns of mus-
cle histopathological changes in LGMD2A is a very
informative step in clinical diagnosis, helpful in estab-
lishing diagnostic strategies in LGMD patients.
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